Clinical Trials on Tuberculosis, Spinal in Korea, Republic of

Total 547 results

Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Hoffmann-La Roche

Terminated

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Spondylitis, Ankylosing

Belgium, Czech Republic, France, Germany, Italy, Spain, United States, Canada, Poland, South Africa, United Kingdom, Australia, Denmark, Netherlands, Bulgaria, India, Lithuania, Brazil, Slovakia
Pfizer

Completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE)

Arthritis, Psoriatic

Belgium, United States, Canada, Spain, Australia, Taiwan, Czechia, Hungary, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Brazil, Bulgaria
National Cancer Institute (NCI)

Terminated

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Neurofibromatosis Type 1 | Plexiform Neurofibroma | Spinal Cord Neurofibroma

United States
Eli Lilly and Company

Withdrawn

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) (SPIRIT A1)

Spondylitis, Ankylosing

Spain, United States, Hungary, Belgium, France, Mexico, Netherlands, Poland, Russian Federation, Ukraine, United Kingdom, Canada, Argentina, Germany, Czech Republic
Hoffmann-La Roche

Terminated

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

Spondylitis, Ankylosing

Belgium, Czech Republic, France, Germany, Italy, Poland, Spain, United States, Canada, South Africa, United Kingdom, Russian Federation, Australia, Bulgaria, India, Lithuania, Brazil, Slovakia
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (FUTURE 2)

Psoriatic Arthritis

Germany, United Kingdom, Belgium, United States, Australia, Thailand, Russian Federation, Czechia, Canada, Poland, Puerto Rico
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Amgen

Completed

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Psoriasis | Psoriatic Arthritis

United States, Canada, United Kingdom, Australia, Hungary, Belgium, Netherlands, Germany, Czechia, Estonia, Latvia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
National Institute of Allergy and Infectious Diseases...
Lederle Laboratories; Hoechst Marion Roussel

Completed

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

HIV Infections | Tuberculosis

United States, Puerto Rico
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Cytokinetics

Terminated

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) (COURAGE OLE)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Spain, Belgium, Ireland, Italy, Netherlands, Sweden
Merit E. Cudkowicz, MD
Massachusetts General Hospital

Active, not recruiting

HEALEY ALS Platform Trial - Master Protocol

Amyotrophic Lateral Sclerosis

United States
Flex Pharma, Inc.

Terminated

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

Motor Neuron Disease

United States
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Massachusetts General Hospital
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Clinical Trial Ceftriaxone in Subjects With ALS

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Cytokinetics
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Australia, Canada, Ireland, Spain
Sanofi

Terminated

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)

Amyotrophic Lateral Sclerosis

Netherlands, China, Poland, Italy, Belgium, United States, Canada, France, Germany, Japan, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Orion Corporation, Orion Pharma

Completed

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
Mallinckrodt

Terminated

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Peru, Mexico, Canada, Argentina, Chile, Colombia
Cytokinetics

Completed

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Germany, Canada, Netherlands, France, Ireland, Spain
Cytokinetics

Terminated

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

Amyotrophic Lateral Sclerosis

United States, Germany, Spain, Australia, United Kingdom, Canada, France, Belgium, Denmark, Ireland, Italy, Netherlands, Poland, Portugal, Sweden, Switzerland
Cytokinetics

Completed

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Amyotrophic Lateral Sclerosis

Canada, United States, Netherlands, France, United Kingdom, Belgium, Germany, Spain, Ireland, Italy, Portugal
Orion Corporation, Orion Pharma

Terminated

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension (REFALS-ES)

Amyotrophic Lateral Sclerosis

Canada, United States, Australia, Germany, Belgium, Finland, Spain, Austria, Italy, France, Ireland, Netherlands, Sweden, United Kingdom
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Cytokinetics

Completed

A Study for Patients Who Completed VITALITY-ALS (CY 4031) (VIGOR-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
Children's Hospital of Philadelphia
Eli Lilly and Company; University of Pennsylvania; Takeda; National Institute of... and other collaborators

Recruiting

The Myelin Disorders Biorepository Project (MDBP)

Mucopolysaccharidoses | Leukoencephalopathies | Leukodystrophy | Adrenoleukodystrophy | Adrenomyeloneuropathy | X-linked Adrenoleukodystrophy | Gangliosidoses | Metachromatic Leukodystrophy | Krabbe Disease | Refsum Disease | Cadasil | Sjogren-Larsson Syndrome | Allan-Herndon-Dudley Syndrome | White Matter Disease | GM2... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
Radius Health, Inc.

Completed

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Osteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae

United States, Poland, Italy
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

Spain, Belgium, Germany, Italy, United Kingdom, Denmark, Mexico, Netherlands, Switzerland
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Choriocarcinoma | Embryonal Carcinoma | Mixed Germ Cell Tumor | Central Nervous System Nongerminomatous Germ Cell Tumor | Immature Teratoma | Malignant Teratoma | Pineal Region Germ Cell Tumor | Pineal Region Immature Teratoma | Pineal Region Yolk Sac Tumor | Suprasellar Germ Cell Tumor

United States, Australia, Canada, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Rhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Recruiting

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Multiple Sclerosis | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Psoriasis | Systemic Scleroderma | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Psoriatic Arthritis | Inflammatory Bowel Disease | Autoimmune Disease | Sjogren...

United States, Canada
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Liver | Metastatic Breast Carcinoma | Metastatic Malignant Neoplasm in the Lung and other conditions

United States, Canada, Saudi Arabia, Korea, Republic of
National Cancer Institute (NCI)

Completed

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Brain Stem Neoplasm | Pineal Region Neoplasm | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Head and Neck Squamous Cell Carcinoma | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam

Clinical Trials on Tuberculosis, Spinal in Korea, Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations